AFINITOR® (everolimus) Additional Resources | Advanced Renal Cell Carcinoma | AFINITOR.com
AFINITOR® (everolimus) Logo | AFINITOR.com
AFINITOR is a once-daily oral inhibitor of mTOR (mammalian target of rapamycin) for patients with advanced renal cell carcinoma (RCC) whose disease has progressed on or after treatment with VEGF-targeted therapy
Afinitor International Website  |  For Healthcare Professionals Outside the U.S.  |  US Residents
Publications Library

Key Events

Additional Resources


Stay informed on the latest information, including news related to AFINITOR and other updates.

Additional Resources

Explore links to a variety of organizations that provide information and support to healthcare professionals and people affected by cancer. The following organizations and websites are independently operated and not managed by Novartis. Novartis assumes no responsibility for any information they may provide.

Europe

Asociacion Espanola de Hematologia y Hemoterapia
www.aehh.org

Cancer Care, Inc.
www.cancercare.org

Cancer Research UK
science.cancerresearchuk.org

Cancer World / Cancer Europe
www.cancerworld.com

European Organization for Research and Treatment of Cancer
www.eortc.be

European Society for Medical Oncology
www.esmo.org

Federation of European Cancer Societies
www.fecs.be

Karolinska Institutet
ki.se/?l=en

German Cancer Research Center
www.dkfz-heidelberg.de

The European Agency for the Evaluation of Medicina
www.emea.europa.eu



International

International Agency for Research on Cancer
www.iarc.fr

International Union Against Cancer
www.uicc.org



US

American Cancer Society (ACS)
www.cancer.org

American Society of Clinical Oncology (ASCO)
www.asco.org

American Society for Therapeutic Radiology and Oncology (ASTRO)
www.astro.org

American Association of Cancer Research
www.aacr.org

American Foundation for Urologic Disease
www.auafoundation.org

Oncology Nursing Society (ONS)
www.ons.org